Inhibikase Therapeutics, Inc. (IKT) vs Palisade Bio, Inc. (PALI)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Palisade Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PALI
Palisade Bio, Inc.
$1.49HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IKT vs PALI
growth of $100 · dividends reinvested · last 6yIKT -96.6% (-43.2%/yr)PALI -100.0% (-72.7%/yr)IKT compounded faster over this window
Log scale — wide-divergence pair
IKT PALI
IKT vs PALI: by the numbers
- •IKT is the larger company ($261M vs $259M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | IKT | PALI |
|---|---|---|
| P/S ratio | N/A | 517.27 |
| P/B ratio | 1.71 | 2.12 |
Profitability
| Metric | IKT | PALI |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -6388.20% |
| ROE | -39.55% | -26.24% |
| ROIC | -42.92% | -28.96% |
Growth (annualized)
| Metric | IKT | PALI |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | -76.02% |
Frequently asked
- How have IKT and PALI total returns compared?
- Over the past 5 years, IKT delivered -29.10% and PALI delivered -76.02% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.